APA (7th ed.) Citation

C, A., F, G., F, P., JA, D., S, G., & B, C. (2019). Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of neurology, 266(3), 726. https://doi.org/10.1007/s00415-019-09195-2

Chicago Style (17th ed.) Citation

C, Alcalá, Gascón F, Pérez-Miralles F, Domínguez JA, Gil-Perotín S, and Casanova B. "Treatment with Alemtuzumab or Rituximab After Fingolimod Withdrawal in Relapsing-remitting Multiple Sclerosis Is Effective and Safe." Journal of Neurology 266, no. 3 (2019): 726. https://doi.org/10.1007/s00415-019-09195-2.

MLA (9th ed.) Citation

C, Alcalá, et al. "Treatment with Alemtuzumab or Rituximab After Fingolimod Withdrawal in Relapsing-remitting Multiple Sclerosis Is Effective and Safe." Journal of Neurology, vol. 266, no. 3, 2019, p. 726, https://doi.org/10.1007/s00415-019-09195-2.